Karani Asset Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$357K Sell
9,710
-19,630
-67% -$930K 0.29% 49
2025
Q4
$1.49M Sell
29,340
-7,669
-21% -$392K 1.22% 20
2025
Q3
$2.05M Buy
37,009
+5,884
+19% +$344K 1.64% 21
2025
Q2
$2.15M Buy
31,125
+493
+2% +$33.5K 2.08% 19
2025
Q1
$2.13M Buy
30,632
+6,844
+29% +$565K 2.25% 21
2024
Q4
$2.05M Buy
+23,788
New +$2.57M 1.91% 21
2023
Q3
$2.21M Sell
24,330
-25,330
-51% -$2.23M 3.19% 16
2023
Q2
$4.02M Hold
49,660
4.05% 12
2023
Q1
$3.95M Sell
49,660
-11,684
-19% -$829K 4.19% 8
2022
Q4
$4.15M Sell
61,344
-23,700
-28% -$1.39M 4.84% 5
2022
Q3
$4.24M Buy
85,044
+1,230
+1% +$65.9K 4.3% 7
2022
Q2
$4.67M Sell
83,814
-28,116
-25% -$1.56M 4.32% 10
2022
Q1
$6.21M Buy
111,930
+13,810
+14% +$709K 3.36% 14
2021
Q4
$5.5M Buy
98,120
+236
+0.2% +$12.8K 2.72% 20
2021
Q3
$4.7M Buy
97,884
+1,460
+2% +$70.6K 2.28% 23
2021
Q2
$4.04M Buy
96,424
+638
+0.7% +$24.7K 2.09% 23
2021
Q1
$3.23M Buy
95,786
+3,056
+3% +$109K 1.9% 25
2020
Q4
$3.24M Sell
92,730
-13,300
-13% -$460K 1.92% 25
2020
Q3
$3.68M Hold
106,030
2.47% 21
2020
Q2
$3.47M Sell
106,030
-8,100
-7% -$258K 2.69% 18
2020
Q1
$3.44M Buy
114,130
+31,330
+38% +$933K 3.67% 12
2019
Q4
$2.4M Buy
+82,800
New +$2.29M 2.22% 16

Other funds holding NVO

Karani Asset Management's NVO Position: Q1 2026 in Review

Karani Asset Management reduced its Novo Nordisk (NVO) stake by 67% in Q1 2026, selling an estimated $930K and leaving 9,710 shares worth $357K. The position accounts for 0.29% of the portfolio, ranked #49.

Karani Asset Management first reported a position in NVO in Q4 2019 and has held it in 22 quarters since. The position peaked at $6.21M in Q1 2022. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Karani Asset Management held 9,710 shares of Novo Nordisk worth $357K as of Q1 2026.
  • Karani Asset Management sold 19,630 Novo Nordisk shares in Q1 2026, an estimated $930K.
  • Novo Nordisk made up 0.29% of Karani Asset Management's portfolio in Q1 2026, its #49 holding.
  • Karani Asset Management first reported a position in Novo Nordisk in Q4 2019 and has held it in 22 quarters since.
  • Karani Asset Management's Novo Nordisk position peaked at $6.21M in Q1 2022.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Karani Asset Management's 13F filing for Q1 2026, filed 15 May 2026.